Target: ₹3,000
CMP: ₹2,221.50
With revenue down 0.2 per cent (vs. the Street’s estimated 2.2 per cent rise) and volumes up only 2 per cent (3 per cent), Hindustan Unilever’s Q4 belied expectations. Subdued rural demand, price cuts in mass soap (for a better price-value equation) and keen competition from smaller manufacturers (tea, detergent bars, etc.) hit Q4.
The premium portfolio, though, is strong. It retained a 200 bps corporate market share gained in the last 2-3 years (inflationary period) despite the competitive onslaught. We believe the behemoth is being re-imagined under Rohit Jawa’s leadership, amid a muted macro context. Thus, we are optimistic about better growth in FY25, but expect it to be more gradual.
The termination of GSK consignment-selling agreement is expected to dent EBITDA margin 50- 60bps in coming quarters. Management, though, indicated bulking up gross margins to FY20 levels (or adding 270bps), while continuing to invest in brands (keener competition and for premiumisation/innovation).
We retain our Buy with a lower 12-month target price of ₹3,000 (₹3,020 earlier), 55x FY26e EPS, 35 per cent potential.
Key risks: Sharp rise in input costs, price-based competition, loss of market share to new/smaller manufacturer
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.